Cipla gets US FDA tentative nod; stock gains

Cipla has got US FDA tentative nod for HIV-1 drug Viramune generic, reports Business Standard.

May 04, 2012 / 09:27 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Cipla has got US FDA tentative nod for HIV-1 drug Viramune generic. The company also cuts price of generic version Bayer’s cancer drug Nexavar prices by 75%, reports Business Standard.

Cipla touched an intraday high of Rs 326.45 and an intraday low of Rs 318.80. At 09:22 hrs the share was quoting at Rs 324.90, up Rs 7.50, or 2.36%.

It was trading with volumes of 49,149 shares. In the previous trading session, the share closed down 0.02% or Rs 0.05 at Rs 317.40.

first published: May 4, 2012 09:25 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347